Search
Brepocitinib
go.drugbank.com/drugs/DB15003ApprovedInvestigationalBrepocitinib is an oral Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor used to treat dermatomyositis in adults. It inhibits TYK2- and JAK1-mediated cytokine signaling, blocking phosphorylation of signal transducers and activat...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsGW-468816
go.drugbank.com/drugs/DB15099ExperimentalGW-468816 is under investigation in clinical trial NCT00218465 (Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking).
Categories: Receptors, N-Methyl-D-Aspartate, antagonists & inhibitorsPozelimab
go.drugbank.com/drugs/DB15218ApprovedInvestigational[A261120] Pozelimab is a human, monoclonal immunoglobulin G4<sup>P</sup> antibody against the terminal complement protein C5.
Olorofim
go.drugbank.com/drugs/DB15245InvestigationalOlorofim is under investigation in clinical trial NCT03340597 (Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects).
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 SubstratesAvutometinib
go.drugbank.com/drugs/DB15254ApprovedInvestigationalAvutometinib is a small molecule kinase inhibitor targeted against RAF/MEK1, key regulators of the RAS/RAF/MEK/ERK (MAPK) pathway. The MAPK pathway is implicated in variety of cancers, playing a key role in tumor cell proliferation, diff...
Synonyms: N-(3-fluoro-4-((4-methyl-2-oxo-7-((pyrimidin-2-yl)oxy)-2H-1-benzopyran-3-yl)methyl)pyridin-2-yl)-N'-methylsulfuric diamide, Sulfamide, N-(3-fluoro-4-((4-methyl-2-oxo-7-(2-pyrimidinyloxy)-2H-1-benzopyran-3-yl)methyl)-2-pyridinyl)-N'-methyl-Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesCrizanlizumab
go.drugbank.com/drugs/DB15271ApprovedInvestigationalCrizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease. Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Afri...
Risdiplam
go.drugbank.com/drugs/DB15305ApprovedInvestigationalRisdiplam is an orally bioavailable mRNA splicing modifier used for the treatment of spinal muscular atrophy (SMA). It increases systemic SMN protein concentrations by improving the efficiency of SMN2 gene transcription. This mechanism o...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesDanicopan
go.drugbank.com/drugs/DB15401ApprovedInvestigationalParoxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematologic disease characterized by hemolysis, thrombophilia, and bone marrow dysfunction. Both hemolysis and thrombophilia are mediated primarily by the complement system. St...
Synonyms: (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide, (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidine-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridine-2-yl)-4-fluoropyrrolidine-2-carboxamideCategories: P-glycoprotein inhibitorsYersinia pestis 195/p antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15461InvestigationalYersinia pestis 195/p antigen (formaldehyde inactivated) is under investigation in clinical trial NCT02596308 (Immunogenicity and Safety of Subunit Plague Vaccine).
Synonyms: Yersinia pestis 195/p antigen (formaldehyde inactivated)Sotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigationalSotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer. This mutation makes up >50% of all KRAS...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates